To include your compound in the COVID-19 Resource Center, submit it here.

Arvinas brings its first PROTAC to the clinic

Arvinas said it has started dosing metastatic castration-resistant prostate cancer patients in a

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE